Chemical Target-Binding Compositions

• US 20080200434A1
• Filed: 03/12/2008
• Published: 08/21/2008
• Est. Priority Date: 09/14/2006
• Status: Abandoned Application

• Current Assignee: Therabit, Inc.
• Original Assignee: Therabit, Inc.
• Inventors: Daniloff, George Y.
• Application Number:
  US12/047,076
• Publication Number:
  US 20080200434A1
• Time in Patent Office: Days
• US Class Current: 514/64
• CPC Class Codes: A61K 31/69 Boron compounds

Abstract

Herein is described compositions and methods for modulating and regulating the concentration of a chemical target in an organism or in an ecosystem. In one embodiment, the concentration is regulated such that it is maintained below or above a certain threshold, thus avoiding toxic or harmful effects of the chemical target. The described compositions may, for example, be implanted in a human body or placed in the ecosystem. The compositions comprise binding moieties that reversibly bind to a chemical target in the organism or ecosystem. The binding capacity and the binding constants for a chemical target are designed such that the composition maintains the concentration of the chemical target substantially within a beneficial range of concentrations.

Claims

1. A pharmaceutical composition comprising a biocompatible binding component comprising a binding moiety capable of reversibly binding with a chemical target, wherein the pharmaceutical composition is capable of regulating the concentration of the chemical target in a physiological fluid of a patient.

2. The pharmaceutical composition of claim 1, further comprising the chemical target.

3. The pharmaceutical composition of claim 1, wherein the binding constant of the binding moiety is complementary to the beneficial range of concentrations of the chemical target in the physiological fluid.

4. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is capable of maintaining the concentration of the chemical target substantially within a predetermined range for a predetermined period of time.

5. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is suitable for administration to a patient.

6. The pharmaceutical composition of claim 5, wherein the pharmaceutical composition is suitable to be administered to a patient parenterally, orally, rectally, vaginally, sublingually, nasally, topically, or transdermally.

7. The pharmaceutical composition of claim 5, wherein the pharmaceutical composition is suitable to be administered to a patient via implantation.

8. The pharmaceutical composition of claim 1, further comprising a pharmaceutically acceptable carrier.

9. The pharmaceutical composition of claim 8, wherein the pharmaceutically acceptable carrier is a polymer matrix.

10. The pharmaceutical composition of claim 8, wherein the pharmaceutically acceptable carrier is a hydrogel.

11. The pharmaceutical composition of claim 8, wherein the binding component is dispersed within the pharmaceutically acceptable carrier.

12. The pharmaceutical composition of claim 10, wherein the binding moieties are covalently attached to the hydrogel.

13. The pharmaceutical composition of claim 4, wherein the predetermined range is the beneficial range of concentrations for the chemical target in the physiological fluid.

14. The pharmaceutical composition of claim 4, wherein the predetermined range includes concentrations that are about 20% or more of the minimum beneficial concentration for the chemical target in the physiological fluid.

15. The pharmaceutical composition of claim 4, wherein the predetermined range includes concentrations that are about 500% or less of the maximum beneficial concentration for the chemical target in the physiological fluid.

16. The pharmaceutical composition of claim 4, wherein the predetermined period of time is about 1 hr.

17. The pharmaceutical composition of claim 4, wherein the predetermined period of time is about 24 hr.

18. The pharmaceutical composition of claim 4, wherein the predetermined period of time is about 1 week.

19. The pharmaceutical composition of claim 4, wherein the predetermined period of time is about 4 weeks.

20. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is in the form of a solution.

21. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is in the form of a hydrogel, hydrogel particles, hydrogel beads, or a hydrogel paste.

22. The pharmaceutical composition of claim 1, wherein the binding component comprises a polymer.

23. The pharmaceutical composition of claim 1, wherein the binding component comprises an elastomer.

24. The pharmaceutical composition of claim 1, wherein the binding component comprises a plurality of polymers that form a hydrogel upon mixing.

25. The pharmaceutical composition of claim 5, wherein the binding component is bioresorbable.

26. The pharmaceutical composition of claim 2, wherein the chemical target is selected from nutrients, hormones, drugs, toxins, cells, vitamins, antibodies, proteins, nucleic acids, electrolytes, and enzymes.

27. The pharmaceutical composition of claim 2, wherein the chemical target is a nutrient.

28. The pharmaceutical composition of claim 27, wherein the chemical target is glucose.

29. The pharmaceutical composition of claim 28, wherein the binding component comprises a plurality of glucose binding moieties.

30. The pharmaceutical composition of claim 29, wherein the binding constant of the binding moieties is such that the binding moieties to be in equilibrium with the physiological fluid when the concentration of glucose in the physiological fluid is in the range of about 0.1 mM to about 50 mM.

31. The pharmaceutical composition of claim 30, wherein the binding component comprises boronic acid, boronate ion, arsenious acid, arsenite ion, telluric acid, tellurate ion, germanic acid, germanate ion, or analogs or derivatives thereof.

32. The pharmaceutical composition of claim 31, wherein the binding component comprises phenylboronic acid or analogs or derivatives thereof.

33. The pharmaceutical composition of claim 28, wherein the binding component preferentially binds glucose in vivo over metabolites present in physiological fluids containing alpha-hydroxy or beta-diketone groups.

34. The pharmaceutical composition of claim 30, wherein the glucose binding moiety is covalently attached to a polymeric matrix.

35. The pharmaceutical composition of claim 34, wherein the glucose binding moiety is phenylboronic acid or derivatives thereof.

36. The pharmaceutical composition of claim 2, wherein the chemical target is a metabolite and the concentration of the metabolite in the pharmaceutical composition is between about 0.2 and 10 times the nominal concentration of the metabolite in the physiological fluid.

37. The pharmaceutical composition of claim 2, wherein the chemical target is selected from endogenous autologous hormones, endogenous autologous cytokines, thyroid stimulating hormones, toxins, herbicides, pesticides, fertilizers, chemical warfare agents, environmental pollutants, heavy metals, viruses, prions, and plasmids.

38. The pharmaceutical composition of claim 2, wherein the chemical target is selected from endogenous PDGF, FGF, bone morphogenic protein, EGF, TGF-β

, carbon monoxide, triiodothyronine, nitric oxide, thyroxine, and autologous or synthetic insulin.

39. The pharmaceutical composition of claim 7, further comprising angiogenic material selected from hydrophilic polyvinylidene fluoride, mixed cellulose esters, e-PTFE, polyester, polyvinyl chloride, polypropylene, polyethylene, polysulfone, polyethersulfone, cellulose acetate, nylon, polycarbonate, polymethylmethacrylate, and mixtures thereof.

40. The pharmaceutical composition of claim 39, further comprising a layer of bioprotective material.

41. The pharmaceutical composition of claim 40, wherein the bioprotective material comprises a material selected from polyurethane, polytetrafluoroethylene, polypropylene, polyethylene, and polysulfone.

42. The pharmaceutical composition of claim 40, wherein the layer of bioprotective material is located between the binding component and the angiogenic material.

43. The pharmaceutical composition of claim 40, wherein the angiogenic material and the bioprotective layer together comprise a composite membrane.

47. A method of regulating the concentration of a chemical target in a physiological fluid of a patient, comprising contacting the physiological fluid with the composition of claim 1.

48. A method of lowering the concentration of a chemical target in a physiological fluid in a patient, comprising contacting the physiological fluid with the composition of claim 1.

49. A method of increasing the concentration of a chemical target in a physiological fluid in a patient, comprising contacting the physiological fluid with the composition of claim 1.

50. The method of claim 47, wherein the composition is maintained outside of the body of the patient during the contacting.

51. The method of claim 47, wherein the composition is administered to the patient and the contacting occurs in vivo.

52. The method of claim 51, wherein the composition is administered parenterally, orally, rectally, vaginally, sublingually, nasally, topically, or transdermally.

53. The method of claim 51, wherein the composition is implanted into the patient.

44. A pharmaceutical composition for treating diabetes comprising a biocompatible binding component capable of reversibly binding glucose, wherein the pharmaceutical composition is in a dosage form capable of contacting the physiological fluid of a patient suffering from diabetes for a predetermined length of time.

45. The pharmaceutical composition of claim 44, wherein the pharmaceutical composition is in the form of a bolus.

46. The pharmaceutical composition of claim 44, further comprising glucose.

54. A method for regulating the concentration of glucose in the blood of a patient comprising contacting the blood of the patient with a pharmaceutical composition comprising a therapeutic amount of a biocompatible binding component capable of reversibly binding glucose.

55. The method of claim 54, wherein the patient suffers from diabetes.

56. The method of claim 54, wherein the method is effective for reducing glycemic variations in the patient.

57. The method of claim 54, wherein the method is effective for reducing oxidative stress in the patient.

58. The method of claim 54, wherein the pharmaceutical composition is capable of the reversible binding of glucose when the physiological fluid has a glucose concentration within the range of 0.1 mM to 50 mM.

59. The method of claim 54, wherein the pharmaceutical composition is implanted in the body of the patient, and the contacting occurs in vivo.

60. The method of claim 59, wherein the pharmaceutical composition is implanted into muscle tissue, subcutaneous tissue, bone, liver tissue, the peritoneal cavity, the thoracic cavity, a blood vessel, lung tissue, brain tissue, the cerebrospinal canal, eye tissue, kidney tissue, spleen tissue, fatty tissue, or bladder tissue.

61. The method of claim 59, wherein the pharmaceutical composition regulates the concentration of glucose in the local tissue.

62. The method of claim 59, wherein the pharmaceutical composition regulates the systemic concentration of glucose.

63. The method of claim 54, wherein the contacting occurs outside of the body of the patient.

64. The method of claim 54, wherein the pharmaceutical composition further comprises glucose.

65. A method for regulating the concentration of a chemical target in a physiological fluid of a patient, the method comprising:

(a) administering to the patient a composition capable of binding to the chemical target; and

(b) administering to the patient the chemical target.

66. A composition for regulating the concentration of a chemical target in an aqueous environment of an ecosystem, comprising a binding component comprising a binding moiety capable of reversibly binding with a chemical target, wherein the binding constant of the binding moiety is complementary to the beneficial range of concentrations for the chemical target in the aqueous environment.

67. The composition of claim 66, wherein the composition is contained within a containment structure comprising a barrier that allows diffusion of the chemical target across the barrier.

68. The composition of claim 66, wherein the composition is capable of maintaining the concentration of the chemical target substantially within a predetermined range for a predetermined period of time.

69. The composition of claim 68, wherein the predetermined range the beneficial range of concentrations for the chemical target in the aqueous environment.

70. The composition of claim 68, wherein the predetermined range includes concentrations that are about 20% or more of the minimum beneficial concentration for the chemical target in the aqueous environment.

71. The composition of claim 68, wherein the predetermined range includes concentrations that are about 500% or less of the maximum beneficial concentration for the chemical target in the aqueous environment.

72. The composition of claim 66, wherein the composition is in the form of beads.

73. The composition of claim 66, wherein the composition is in the form of a hydrogel.

74. A method for regulating the concentration of a chemical target in an aqueous environment of an ecosystem, the method comprising delivering to the aqueous environment the composition of claim 66.